This page shows the latest evobrutinib news and features for those working in and with pharma, biotech and healthcare.
Merck KGaA is putting its BTK inhibitor evobrutinib to the test in two phase 3 multiple sclerosis (MS) trials, the first drug in the class to reach that stage for the ... The new trials – dubbed EVOLUTION RMS 1 and 2 – will compare twice-daily oral
Patients had fewer lesions on evobrutinib than placebo. BTK inhibitors are already establishing themselves as important new drugs in cancer, but Merck KGaA has the first data suggesting they could also ... That mechanism also forms the basis of Merck’s
Merck KGaA is among the front-runners among companies developing BTK inhibitors for inflammatory diseases, with its evobrutinib progressing to phase IIb testing in rheumatoid arthritis last September, while Bristol-Myers
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....